Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a diagnosis of primary immune thrombocytopenia (ITP) for a minimum of 3 months prior to Screening Visit~* Subject has a platelet count \<30x10\^9/L at Screening and \<35x10\^9/L at Baseline (Visit 2)~* Subject has a current or history of a peripheral blood smear consistent with ITP~* Subject has responded to previous ITP therapy (according to the judgment of the investigator)~Exclusion Criteria:~* Subject has an immunoglobulin G (IgG) level \<=6g/L at Screening Visit~* Subject has a partial thromboplastin time (PTT) \>=1.5x upper limit of normal (ULN) or International Normalized Ratio (INR) \>=1.5 at Screening Visit~* Subject has renal and/or liver impairment defined as:~  * Serum creatinine level of \>=1.4 mg/dL for females and \>=1.5 mg/dL for males at Screening Visit~* Subject has planned an elective surgical procedure in the coming 6 months~* Subject has evidence of a secondary cause of primary immune thrombocytopenia purpura~* Subject has a history of clinically relevant ongoing chronic infections~* Subject has a family history of primary immunodeficiency~* Subject has a clinically relevant active infection or has had a serious infection within 6 weeks prior to the first dose of IMP~* Subject has a history of known inflammatory bowel disease, diverticular disease, and gastric or esophageal ulceration~* Subject has experienced gastrointestinal bleed in the last 6 months prior to Screening Visit and/or has current gastritis or esophagitis~* Subject has a medical history of thrombosis~* Subject has a history of coagulopathy disorders other than ITP~* Subject has received a live vaccination within 8 weeks prior to the Baseline Visit; or intends to have a live vaccination during the course of the study or within 7 weeks following the final dose of IMP~* Subject has had prior treatment with rituximab in the 6 months prior to the Baseline Visit~* Subject has not completed the washout period for the immunosuppressants, biologics and other therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- UCB7665 4 mg/kg (Type: EXPERIMENTAL): Participants in this arm received 5 subcutaneous (sc) doses of UCB7665 (rozanolixizumab) 4 milligram per kilograms (mg/kg) at 1-week intervals.
- UCB7665 7 mg/kg (Type: EXPERIMENTAL): Participants in this arm received 3 sc doses of UCB7665 (rozanolixizumab) 7 mg/kg at 1-week intervals.
- UCB7665 10 mg/kg (Type: EXPERIMENTAL): Participants in this arm received 2 sc doses of UCB7665 (rozanolixizumab) 10 mg/kg at 1-week intervals.
- UCB7665 15 mg/kg (Type: EXPERIMENTAL): Participants in this arm received 1 sc dose of UCB7665 (rozanolixizumab) 15 mg/kg.
- UCB7665 20 mg/kg (Type: EXPERIMENTAL): Participants in this arm received 1 sc dose of UCB7665 (rozanolixizumab) 20 mg/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).